In registry studies of CAR-T products that have been marketed globally, patients with
relapsed or refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) have been enrolled to
receive CAR-T infusion in combination with tyrosine kinase inhibitors (BTKi) or immune
checkpoint inhibitors (PD-1 or PD-L1 antibodies), with objective remission rate (ORR) for
CAR-T in combination with BTKi ranging from 83.3%-100% and complete remission rate (CRR) were
33.3-75%. The ORRs for objective remission rates for CAR-T combined with PD1/PD-L1 ranged
from 50-91% and CRRs were 33.3-64%, respectively. With regard to safety, no dose-limiting
toxic (DLT) occurred and the incidence of other adverse reactions was low, and studies
demonstrated that BTKi or PD-1/PD-L1 antibodies could further enhance the responsiveness and
durability of anti-CD19 CAR-T cell therapy. However, there are no studies exploring the
efficacy and safety of clinical regimens using BTKi + radiotherapy ± chemotherapy as a
bridging regimen to treat r/r B-NHL in combination with BTKi and/or PD-1 inhibitor after
CAR-T cell infusion. In real-world applications of commercial CAR-T, CAR-T therapy combined
with BTKi or PD-1/PD-L1 antibodies may further improve response rates and remission
persistence in r/r B-NHL patients receiving CAR-T infusion back, with efficacy benefits while
ensuring a manageable safety profile. Therefore, our center plans to conduct a phase II
clinical study of Regent CAR-T 001(A phase II study of BTKi+radiotherapy±chemotherapy
bridging before CAR-T cell therpay in combination with BTKi±PD-1 inhibitor for r/r B-NHL).